Cargando…

HER2 testing in gastric cancer: results of a German expert meeting

Valid HER2 testing is essential for optimal therapy of patients with HER2-positive gastric cancer and the correct use of first-line chemotherapy. While testing for HER2 status in breast cancer is routinely performed, this is not the case for HER2 testing in gastric cancer and it is usually only perf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lordick, Florian, Al-Batran, Salah-Eddin, Dietel, Manfred, Gaiser, Timo, Hofheinz, Ralf-Dieter, Kirchner, Thomas, Kreipe, Hans H., Lorenzen, Sylvie, Möhler, Markus, Quaas, Alexander, Röcken, Christoph, Rüschoff, Josef, Tannapfel, Andrea, Thuss-Patience, Peter, Baretton, Gustavo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Review – Clinical Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384945/ https://www.ncbi.nlm.nih.gov/pubmed/28285403 http://dx.doi.org/10.1007/s00432-017-2374-x

Ejemplares similares

Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract
por: Baretton, Gustavo B., et al.
Publicado: (2023)

HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
por: Rüschoff, Josef, et al.
Publicado: (2010)

Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)
por: Tintelnot, Joseph, et al.
Publicado: (2020)

Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2‐Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
por: Al‐Batran, Salah‐Eddin, et al.
Publicado: (2020)

Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma
por: Lordick, Florian, et al.
Publicado: (2021)

RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV
por: Lorenzen, Sylvie, et al.
Publicado: (2020)

HER-2-Positive Tumors: A Continuously Evolving Field in Cancer Research
por: Hofheinz, Ralf, et al.
Publicado: (2023)

The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing
por: Werner, Dominique, et al.
Publicado: (2014)

Evaluation of EGFR inhibitor‐mediated acneiform skin toxicity within the double‐blind randomized EVITA trial: A thorough gender‐specific analysis using the WoMo score
por: Gaiser, Maria R., et al.
Publicado: (2019)

Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321)
por: Tintelnot, Joseph, et al.
Publicado: (2023)

Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer
por: Lordick, Florian, et al.
Publicado: (2023)

Perspectives on the Management of Oligometastatic Disease in Esophago-Gastric Cancer
por: Goetze, Thorsten Oliver, et al.
Publicado: (2022)

Physical basis of the ‘magnification rule’ for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer
por: Scheel, Andreas H., et al.
Publicado: (2018)

Her2/neu testing in gastric cancer: evaluating the risk of sampling errors
por: Warneke, V. S., et al.
Publicado: (2013)

Visualisation of HER2 homodimers in single cells from HER2 overexpressing primary formalin fixed paraffin embedded tumour tissue
por: Peckys, Diana B., et al.
Publicado: (2019)

Prognostic Impact of mRNA Expression Levels of HER1–4 (ERBB1–4) in Patients with Locally Advanced Rectal Cancer
por: Kripp, Melanie, et al.
Publicado: (2016)

Professor Germane and the Medical Experts
por: Ritchie, Josiah
Publicado: (1891)

VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
por: Thomaidis, Thomas, et al.
Publicado: (2014)

Multimodal Treatment Strategies in Esophagogastric Junction Cancer: a Western Perspective
por: Goetze, Thorsten Oliver, et al.
Publicado: (2019)

Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status
por: Rüschoff, Josef, et al.
Publicado: (2022)

AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer
por: Kripp, Melanie, et al.
Publicado: (2017)

Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma
por: Werner, Dominique, et al.
Publicado: (2013)

Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review
por: Chiorean, Elena Gabriela, et al.
Publicado: (2019)

Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma
por: Högner, Anica, et al.
Publicado: (2021)

Immunotherapy in Squamous Cell Cancer of the Esophagus
por: Thuss-Patience, Peter, et al.
Publicado: (2022)

German Hospital Development: An Expert Continental Review
Publicado: (1914)

Quality assessment of HER2 testing by monitoring of positivity rates
por: Choritz, Harald, et al.
Publicado: (2011)

Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer
por: Knödler, Maren, et al.
Publicado: (2018)

Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
por: Harder, J, et al.
Publicado: (2012)

MYC gene amplification is a rare event in atypical fibroxanthoma and pleomorphic dermal sarcoma
por: Gaiser, Timo, et al.
Publicado: (2018)

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
por: Türeci, O, et al.
Publicado: (2019)

Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) – a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)– the AIO/ CALGP/ ACO- GAIN-trial –
por: Goetze, Thorsten O., et al.
Publicado: (2020)

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas
por: von Minckwitz, Gunter, et al.
Publicado: (2005)

Correction: Phase I clinical study of the recombinant antibody-toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas
por: von Minckwitz, Gunter, et al.
Publicado: (2006)

EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group
por: Wagner, Anna Dorothea, et al.
Publicado: (2019)

Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma – the phase III “PREVENT”- (FLOT9) trial of the AIO /CAOGI /ACO
por: Götze, Thorsten O., et al.
Publicado: (2021)

Testung auf Mismatch-Reparatur-Defizienz und Mikrosatelliteninstabilität: Eine fokussierte Aktualisierung
por: Rüschoff, Josef, et al.
Publicado: (2023)

For her own good. 150 years of the experts' advice to women
Publicado: (1979)

She adapts to her student: An expert pragmatic speaker tailoring her referring expressions to the Layman listener
por: Greco, Claudio, et al.
Publicado: (2023)

The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer
por: Atmaca, Akin, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ud81flqas8v4neqkhgdoo0tjuk